On August 11, 2022, Dr. Monica Bertagnolli, a director of the Leap Therapeutics, Inc., informed the Company that she will be resigning as a director, effective August 12, 2022, as a result of her appointment as the 16th Director of the National Cancer Institute (NCI) by the Biden administration. Dr. Bertagnolli's departure is not a result of any disagreement with the Company relating to the Company's operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +2.52% | +16.07% | -21.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.59% | 81.16M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- LPTX Stock
- News Leap Therapeutics, Inc.
- Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director